Ann: Opthea Initiates OPT-302 Diabetic Macular Edema Trial, page-45

Hi Resurgam,

Most tend to run into a key binary event.

IIL. I think it simply ran too hard on the Trump advisor hype and congress owning stock. Even when it retreated though it was still trading well higher than the base it had formed over a year or so.

RAP. Maybe once bitten, twice shy, for investors. Many will have memories of price cratering on trial results, not so long ago. Could explain the hesitation.

Other reasons a bio might drag its tail into a key event could be the market doesn't regard the trial as significant enough (stage, end point or potential market size) the company's cash balance may be poor and a raise is expected, or mgmt have a poor track record or low credibility with investors.